Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

323.48 +10.02 (+3.20%)
Official Closing Price Updated: 7:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,694,290
Open 312.65
Bid (Size) 323.40 (1)
Ask (Size) 324.75 (1)
Prev. Close 313.46
Today's Range 311.26 - 324.08
52wk Range 196.68 - 324.08
Shares Outstanding N/A
Dividend Yield 1.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Top Stocks to Buy And Watch Today
Dow Jones leaders Chevron (CVX) and Merck (MRK) — in addition to Livent (LTHM), Eli Lilly (LLY), Northrop Grumman (NOC), 
Via Best Stocks
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly Stock Breaks Out To Another Record High As Cancer Data Looms
The company will unveil test results for three cancer drugs in June. 
Via Investor's Business Daily

Performance

YTD
+19.04%
+19.04%
1 Month
+8.82%
+8.82%
3 Month
+29.42%
+29.42%
6 Month
+26.94%
+26.94%
1 Year
+61.95%
+61.95%

More News

Read More
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
Via Benzinga
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Via Benzinga
Executives Sell Around $207M Of 5 Stocks
Via Benzinga
Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting
Via Benzinga
What 7 Analyst Ratings Have To Say About Eli Lilly
Via Benzinga
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
Via Benzinga
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
S&P 500 Falls For 7th Consecutive Week Amid Ongoing Inflation, Federal Reserve Rate Hike Fears
Via Benzinga
Why Eli Lilly' Shares Are Trading Higher Today
Via Benzinga
Why Eli Lilly Shares Are Rising Today
Via Benzinga
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review
Via Investor's Business Daily
PepsiCo And 3 Other Stocks Insiders Are Selling
Via Benzinga
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities
Via iCrowdNewswire
Veterinary Antibiotics Market Research Insight 2022| Key Players are Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale S.A., Crystal Pharma, Dechra Pharmaceuticals PLC, Huvepharma AD, Eli Lilly Company, Elanco, Merck & Co., Inc., Sanofi S.A., Ve
Via iCrowdNewswire
Exposures COVID-19
Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster
Via Investor's Business Daily
How Is The Market Feeling About Eli Lilly?
Via Benzinga
Five Ways To Play A Stock Market Reprieve
Via Investor's Business Daily
Check Out What Whales Are Doing With LLY
Via Benzinga
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Via Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.